Solid Biosciences
CHARLESTOWN, Massachusetts, United States · Biotechnology, Genetics, Healthcare
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for th
Key facts
- Headquarters
- CHARLESTOWN, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Genetics, Healthcare
- Status
- Public (SLDB)
- Website
- www.solidbio.com
- Company page
Recent activity at Solid Biosciences
- : SEC 8-K (8.01): On August 6, 2026, Solid Biosciences Inc. filed a prospectus supplement under its universal shelf registration statement, allowing the offer and sale of up to $200 million of shares of common stock. This filing follows a prior prospectus supplement for an $85 million offering, from which the company has already issued shares resulting in gross sale proceeds of approximately $85 million. The share offerings will be conducted in compliance with the Sales Agreement dated March 13, 2024, with Jefferies LLC. The filing highlights the company's ongoing capital raising efforts without violating existing registration norms, as it ceases the offers under the previous prospectus supplement as of this filing date.
- : SEC 8-K (5.02): On April 10, 2026, Ilan Ganot resigned from his position on the Board of Directors of Solid Biosciences Inc. (the 'Company') as part of a realignment of board class memberships to achieve an equal balance among the three classes. Concurrently, the board appointed Mr. Ganot to fill a vacancy in Class I, which will have a term expiring at the 2028 Annual Meeting of Stockholders. The appointment will be presented to stockholders for advisory ratification at the 2026 Annual Meeting. Importantly, there were no changes to Mr. Ganot's compensation arrangements due to these changes. This event impacts the governance structure of the Company as it ensures compliance with good corporate governance practices.
- : SEC 8-K (8.01): On March 11, 2026, the Company provided an interim clinical update regarding its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The interim data, cut off on February 23, 2026, indicates favorable safety and tolerability in the 40 pediatric participants thus far, with promising results in muscle integrity markers. The treatment involves a unique microdystrophin construct, which has shown significant microdystrophin expression and restoration of critical proteins in muscle tissue. Ongoing dosing is taking place at 15 clinical sites across several countries, suggesting potential progress in this critical therapeutic area for Duchenne muscular dystrophy patients.
- : SEC 8-K (1.01): On March 6, 2026, Solid Biosciences Inc. entered into a Securities Purchase Agreement with certain institutional accredited investors to issue and sell a total of 14,973,257 shares of its common stock at a price of $5.61 per share. Additionally, for investors who prefer, the company will offer pre-funded warrants to purchase 27,807,482 shares at $5.609 each. The Private Placement is scheduled to close on March 9, 2026, contingent upon customary closing conditions. This agreement is strategic for raising capital and expanding operations in the biotech sector.
- : SEC 8-K (1.01): On March 6, 2026, Solid Biosciences Inc. entered into a securities purchase agreement with certain institutional accredited investors for a private placement. The agreement entails the issuance of 14,973,257 shares of common stock at $5.61 per share and pre-funded warrants for 27,807,482 shares at $5.609 each, expected to close around March 9, 2026. The aggregate gross proceeds from this private placement are anticipated to be about $240 million. Key investors include Perceptive Advisors and Bain Capital Life Sciences, among others, with the Company granting indemnification rights to the investors. Additionally, investors have agreed not to trade the Company's securities until after March 11, 2026.
- : SEC 8-K (8.01): On November 3, 2025, the Company announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, evaluating the safety and efficacy of SGT-003, a gene therapy for Duchenne muscular dystrophy. The interim data covers 23 participants dosed as of October 31, 2025, with a plan to dose a total of 30 by early 2026. Strong correlations were observed between the therapy and key biomarkers of muscle integrity, with important implications for treating muscle disorders. This data signifies a potential advancement in the treatment approach for Duchenne muscular dystrophy and reflects ongoing efforts in clinical research across multiple international sites.
- : Solid Biosciences Inc. establishes its leadership in precision genetic medicines and outlines key priorities for its advanced clinical-stage pipeline.
- : Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer • Solid Biosciences
- : Solid Biosciences Announces Closing Of Acquisition Of Aavantibio And Concurrent $75 Million Private Placement
- : Solid Biosciences
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Solid Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2022 | Venture | $9.2M |
| Oct 2020 | Venture | $40.0M |
| Jul 2019 | Venture | $60.0M |
Leadership
- Ilan Ganot, Executive Officer, Director
- Robert Huffines, Director
- Adam Koppel, Director
- Sukumar Nagendran, Director
- Rajeev Shah, Director
- Matthew Arnold, Director
- Adam Stone, Director
- Lynne Sullivan, Director
- Martin Freed, Director
- Ian Smith, Director
- Andrey Zarur, Director
Verified email and direct lines for Solid Biosciences’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Solid Biosciences files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Solid Biosciences in the news
- Letter to the Duchenne Community - Solid Biosciences (Jan 13, 2026)
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire (Oct 01, 2026)
- Letter to the FA Community - Solid Biosciences (Jan 12, 2026)
- Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient - NeurologyLive (Jan 16, 2026)
- Solid Biosciences’ INSPIRE DUCHENNE Study Puts DMD Gene Therapy SGT-003 to the Test - CGTLive® (Jan 20, 2025)
- Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference - GlobeNewswire (Nov 10, 2026)
- The Berko Family - Solid Biosciences (Jul 10, 2025)
- Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire (Sep 02, 2026)
Companies similar to Solid Biosciences
- Elevation Oncology · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Passage Bio · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Crispr Therapeutics · Biotechnology, Genetics, Healthcare, Health Care, Therapeutics
- Oruka Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- seragy holding GmbH · Biotechnology, Genetics, Health Care, Therapeutics
About Solid Biosciences: questions and answers
What does Solid Biosciences do?
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for th
Where is Solid Biosciences headquartered?
Solid Biosciences is headquartered in CHARLESTOWN, Massachusetts, United States.
Has Solid Biosciences raised funding?
Yes. Fundz has recorded 3 funding events for Solid Biosciences. The most recent, $9.2M, was in Dec 2022.
What is the latest news on Solid Biosciences?
On Nov 3, 2025, SEC 8-K (8.01): On August 6, 2026, Solid Biosciences Inc. filed a prospectus supplement under its universal shelf registration statement, allowing the offer and sale of up to $200 million of shares of common stock. This filing follows a prior prospectus supplement for an $85 million offering, from w
Is Solid Biosciences a public company?
Yes. Solid Biosciences is publicly traded under the ticker SLDB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy